Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$65.42 USD

65.42
12,381,051

+0.15 (0.23%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $65.42 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for GILD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Gilead Sciences, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 7,264 6,385 6,520 7,408 24,352
Receivables 4,660 4,777 4,493 4,892 3,582
Notes Receivable 0 0 0 0 0
Inventories 1,787 1,507 1,618 1,683 922
Other Current Assets 2,374 1,774 2,141 2,013 1,440
Total Current Assets 16,085 14,443 14,772 15,996 30,296
Net Property & Equipment 5,317 5,475 5,121 4,967 4,502
Investments & Advances 1,163 1,245 1,309 502 1,488
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 34,768 37,208 41,787 41,234 17,903
Deposits & Other Assets 4,792 4,800 4,963 5,708 7,438
Total Assets 62,125 63,171 67,952 68,407 61,627
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 550 905 705 844 713
Current Portion Long-Term Debt 1,798 2,273 1,516 2,757 2,499
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 3,802 8,059 9,389 7,796 6,547
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 5,130 0 0 0 0
Total Current Liabilities 11,280 11,237 11,610 11,397 9,759
Mortgages 0 0 0 0 0
Deferred Taxes/Income 1,588 2,673 4,356 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 24,469 24,136 26,155 33,773 23,103
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2,039 3,916 4,767 5,016 6,115
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 39,376 41,962 46,888 50,186 38,977
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 6,500 5,550 4,661 3,880 3,051
Retained Earnings 16,304 15,687 16,324 14,381 19,388
Other Equity -56 -29 78 -41 210
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 22,749 21,209 21,064 18,221 22,650
Total Liabilities & Shareholder's Equity 62,125 63,171 67,952 68,407 61,627
Total Common Equity 22,749 21,209 21,064 18,221 22,650
Shares Outstanding 1,246.00 1,254.20 1,254.30 1,253.50 1,265.10
Book Value Per Share 18.26 16.91 16.79 14.54 17.90

Fiscal Year End for Gilead Sciences, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 7,264 6,864 6,667 5,872
Receivables NA 4,660 4,790 4,229 4,162
Notes Receivable NA 0 0 0 0
Inventories NA 1,787 1,663 1,633 1,576
Other Current Assets NA 2,374 2,662 1,757 1,846
Total Current Assets NA 16,085 15,980 14,287 13,456
Net Property & Equipment NA 5,317 5,572 5,540 5,479
Investments & Advances NA 1,163 1,156 1,334 1,327
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 34,768 35,466 36,064 36,662
Deposits & Other Assets NA 4,792 4,200 5,113 4,952
Total Assets NA 62,125 62,373 62,337 61,876
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 550 586 622 627
Current Portion Long-Term Debt NA 1,798 1,793 4,037 2,283
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 3,802 3,714 3,494 3,477
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 5,130 5,852 5,810 4,140
Total Current Liabilities NA 11,280 11,945 13,964 10,528
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 1,588 1,984 2,106 2,401
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 24,469 24,113 22,563 22,956
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 2,088 2,610 5,052
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 39,376 40,131 41,243 40,937
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 6,500 6,279 6,008 5,793
Retained Earnings NA 16,304 16,002 15,138 15,223
Other Equity NA -56 -41 -54 -78
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 22,749 22,242 21,094 20,939
Total Liabilities & Shareholder's Equity NA 62,125 62,373 62,337 61,876
Total Common Equity 0 22,749 22,242 21,094 20,939
Shares Outstanding 1,245.00 1,246.00 1,246.00 1,247.30 1,247.30
Book Value Per Share 0.00 18.26 17.85 16.91 16.79